Back to the Top
In case of an anti-cancer drug that has not shown to be effective
orally for the treatment of lung cancer and is being investigated for
inhalational therapy for treatment of the same, what should be the
starting dose to determine its effiicacy in a mouse model?
The compound has a demonstrated in vitro efficacy (IC50=5 microM).
However, its efficacy in an in vivo situation is very controversial.
In one study, a dose of 6-8 mg/kg of i.p dose has been efficacious
for treatment of lung cancer in mouse
And in another study, a wide range of dose from 10-100 mg/kg in mice
has not been effective in eradicating the tumor.
For local delivery application, as far as I understand the dose needs
to be cut down drastically as compared to the oral dose.
Will an in vitro in vivo correlation work in this condition?(for eg.
a tumor state)?
Any leads would be very helpful and appreciated!!
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "Mouse dose" as the subject
Support PharmPK by using the
Copyright 1995-2011 David W. A. Bourne (firstname.lastname@example.org)